Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
251lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Learning paths
Pick a track — progress rings update as you complete lessons.
151 lessons
8mPeptidesIntermediate
How GLP-1 Receptor Agonists Change Appetite and Energy Regulation
GLP-1 drugs do more than blunt hunger. They change the signals that shape appetite, food reward, and energy balance, which is why the mechanism matters.
8mResearchAdvanced
MOTS-c and Plasma Membrane Repair: What the New Data Means
MOTS-c is moving beyond the vague mitochondrial hype cycle. The newest data suggests it may participate in membrane repair, which changes the recovery conversation.
9mPeptidesIntermediate
Pemvidutide, MASH, and the Liver-Waist Signal: Why Weight Loss Alone Misses the Point
Pemvidutide is interesting because it does not just ask whether body weight falls. It asks whether liver fat, waist size, appetite, and recovery move together in a clean direction.
9mPeptidesIntermediate
August 14, 2026 Peptide Research Signals: What to Watch Next
The newest peptide research batch is less about hype and more about the questions each compound answers. Retatrutide, tesamorelin, BPC-157, GHK-Cu, and MOTS-C all point at different tracking priorities.
9mResearchAdvanced
Retatrutide Progress Check: How to Tell If the Weight You're Losing Is the Right Kind
Scale weight can lie when appetite drops, water shifts, and training changes. This checklist shows the signals that matter more than a single number on the scale.
8mPeptidesIntermediate
The 2026 Peptide Shift: Why Recovery Is Beating the Scale
The new peptide conversation is not just about appetite and fat loss. Recovery, tissue quality, and mitochondrial support are becoming the real filters.
9mPeptidesIntermediate
GLP-1 Adherence Starts With Perceived Competence: Why the Best Plans Feel Simple
People do not stay on GLP-1 plans because they are disciplined forever. They stay on them when the plan feels manageable, repeatable, and clear enough to trust on a busy week.
12mPeptidesIntermediate
Kisspeptin-10 Peptide Guide: What It Does, Fertility Research, and Common Misspellings (Kispeptin)
Kisspeptin-10 sits upstream of GnRH in reproductive endocrinology research. This guide explains mechanism, what people track, dosing as community discussion only, and why Kispeptin searches miss the mark.
9mPeptidesIntermediate
August 2026 Peptide Research Roundup: What Changed for Retatrutide, BPC-157, MOTS-c, and GHK-Cu
The latest peptide research wave is less about hype and more about what survives real-world tracking. Here is the practical read on retatrutide, BPC-157, MOTS-c, and GHK-Cu.
10mResearchAdvanced
Retatrutide Compounding Quality Control: Why the Debate Matters More Than Hype
Retatrutide may dominate the weight-loss discussion, but the market debate is really about quality control, documentation, and whether a plan can survive real life.
9mPeptidesIntermediate
MOTS-C and the Recovery Gap: Why Better Signaling Does Not Automatically Mean Better Recovery
MOTS-C keeps showing up in 2026 because it points at mitochondrial signaling. The trap is assuming that better signaling automatically means better recovery. It does not.
9mPeptidesIntermediate
Retatrutide and the Recovery Tax: Why Appetite Suppression Can Quietly Hurt Results
The hard part of retatrutide is not the first week. It is what happens when appetite falls faster than planning improves. Protein, training, and sleep start to pay the bill.
10mResearchAdvanced
Retatrutide Early Access: What It Signals for Obesity Treatment, Timing, and Body Composition
Retatrutide is moving from conference noise into real-world access. That shift changes the conversation from headline weight loss to who gets treated, what gets monitored, and how body composition holds up.
8mResearchAdvanced
Retatrutide in 2026: Why the Strongest Weight-Loss Signal Still Needs Body-Composition Tracking
Retatrutide is still the loudest metabolic signal in the room. The people who get the best result are the ones who track body composition, not just pounds lost.
8mPeptidesIntermediate
August 2026 Peptide Research Snapshot: Recovery, GLP-1, Collagen, and Mitochondria
The clearest signal in today's peptide research is not one molecule. It is the pattern: recovery peptides, metabolic peptides, collagen support, and mitochondrial tools all need tighter tracking.
9mResearchAdvanced
Retatrutide, Food Noise, and the Protein Floor: A Better Way to Keep Training on Track
When appetite drops, structure matters more. The people who keep the best retatrutide results are the ones who protect protein, training, and hydration before the scale gets noisy.
8mResearchAdvanced
Amycretin Beginner's Guide: Novo's GLP-1 + Amylin Dual Agonist
Amycretin puts GLP-1 and amylin in one molecule — with both a pill and a weekly shot in development. Here's the beginner map before Phase 3 ladders finalize.
8mResearchAdvanced
Amycretin vs CagriSema: One Dual Agonist vs Two-Drug Amylin Stack
Same company family of ideas — GLP-1 + amylin — two product architectures. Here's how amycretin compares to CagriSema without fake head-to-head rankings.
9mPeptidesIntermediate
Eloralintide Beginner's Guide: What LY3841136 Is and Why Amylin Matters
Eloralintide is Lilly's once-weekly selective amylin receptor agonist. If you follow GLP-1s, CagriSema, or retatrutide, this is the next pathway to understand — satiety biology, trial doses, and what the early data actually show.
8mProtocolsIntermediate
How to Reconstitute Eloralintide: Clinical Product vs Research Vials
People searching how to reconstitute eloralintide usually want a retatrutide-style BAC water chart. Here's the honest version — clinical weekly product vs unverified research powder.
8mResearchAdvanced
Eloralintide vs Cagrilintide: Amylin Agonists Compared
Both hit amylin biology. One is Lilly's Phase 3 monotherapy / combo candidate. The other is the amylin half of CagriSema. Here's a clear comparison for people following the next wave of obesity peptides.
8mResearchAdvanced
Eloralintide vs Petrelintide: Lilly vs Roche Amylin Agonists
Two weekly amylin programs, two sponsors, two data shapes. Here's a clear eloralintide vs petrelintide comparison for people following the next obesity wave.
8mResearchAdvanced
Eloralintide Weight Loss Results: Phase 2 Data and What to Watch in Phase 3
Phase 2 put eloralintide on the board with roughly 9–20% mean weight loss at 48 weeks. Here's the results breakdown — and the troubleshooting mindset for plateaus on any amylin or GLP-1 protocol.
6mResearchBeginner
Macupatide Beginner's Guide: Lilly's LY3532226 Pipeline Peptide
Macupatide is the Lilly code name beside eloralintide that most people skip. This beginner guide explains what it is — and what not to invent about dosing yet.
7mResearchAdvanced
Macupatide and Eloralintide: Lilly's Next Amylin Combination Angle
Eloralintide is only half the Lilly amylin headline. Macupatide shows up in the same ClinicalTrials.gov cluster. Here's the combo literacy guide.
8mProtocolsIntermediate
MariTide vs Weekly GLP-1s: Monthly Conjugate vs Weekly Agonists
Weekly vs monthly is the real MariTide comparison. Here's how Amgen's conjugate stacks up conceptually against weekly dual/triple agonists — without fake head-to-heads.
7mResearchAdvanced
Petrelintide Beginner's Guide: Roche/Zealand's Weekly Amylin Analog
Petrelintide is the amylin analog drawing attention for tolerability. This beginner guide covers what it is, what ZUPREME-1 showed, and what to watch next.
8mPeptidesIntermediate
SS-31 (Elamipretide) Dosing Guide: How Much to Take and When
SS-31 dosage searches keep climbing alongside MOTS-c. Here's the practical elamipretide dosing map — daily mg ranges, timing, cycling, and what to track for mitochondrial protocols.
8mResearchAdvanced
Tesamorelin and Waist-First Tracking: The Metrics That Matter Most
Tesamorelin is a body-composition tool, not a bathroom-scale trick. The best results show up when you track the right metrics from the start.
9mPeptidesIntermediate
MOTS-c and the Repair Paradox: Why a Metabolic Signal Is Not the Same as Healing
MOTS-c looks interesting because it can push metabolism in the right direction and still pull repair in the wrong one. The new data are a reminder that pathway activation and tissue healing are not the same thing.
9mResearchAdvanced
Retatrutide, Protein, and Training: The Real-World Checklist for Better Body Composition
Retatrutide changes the appetite game fast. The people who get the best result are the ones who keep protein, training, and waist measurements in view at the same time.
8mResearchAdvanced
2025 Peptide Therapy Review: Why Human Data Still Lags the Hype
A 2025 review makes the same point the peptide world keeps avoiding: some compounds have real human data, and many popular names still do not.
9mResearchAdvanced
Retatrutide Weight-Loss Data: What the New Numbers Mean for Body Composition
Retatrutide is forcing a better conversation about fat loss. The scale matters, but body composition, protein, and strength tell you whether the result will hold.
9mResearchAdvanced
Retatrutide's FDA Watch Tightens After the Latest Obesity Trial Results
Retatrutide keeps stacking strong data, and the latest trial update sharpens the path toward an FDA submission. The bigger story is not just weight loss. It is how the triple-agonist profile may change what obesity medicine expects from a next-wave therapy.
9mResearchAdvanced
Retatrutide and Waist Circumference: Why the Scale Misses the Real Signal
Retatrutide can change weight fast enough to dominate the headline, but the better question is whether the loss is moving the right tissues, the right labs, and the right habits. That is where waist circumference becomes more useful than the scale.
9mResearchAdvanced
The GH-IGF1 Axis Still Explains the Best Peptide Performance Stories
The GH-IGF1 axis keeps showing up in peptide medicine because it links visceral fat, recovery, and lean mass. The trick is separating the clinical signal from the wellness noise.
8mPeptidesIntermediate
BPC-157 Safety in 2026: What the Evidence Actually Says About Recovery and Risk
BPC-157 has a real research footprint, but most of the confidence in the compound still comes from preclinical work. That gap matters when people start talking about safety like the answer is settled.
10mResearchAdvanced
Retatrutide's July 23 Phase 3 Readout Keeps Raising the Ceiling
Retatrutide just posted two more strong phase 3 wins. The new numbers matter, but the bigger story is how phase 1, phase 2, and phase 3 now line up into one very clear dose-response story.
8mPeptidesIntermediate
GHK-Cu and Collagen Repair: What the Research Suggests
GHK-Cu is not a magic skin fix. It is a copper peptide with a real research trail behind collagen support, tissue remodeling, and wound healing.
9mResearchAdvanced
Regeneration or Risk? What the New BPC-157 Review Says About Musculoskeletal Healing
The new BPC-157 review is useful because it separates mechanism from marketing. The peptide looks biologically interesting, but the human evidence is still thin.
9mResearchAdvanced
Retatrutide Phase 3 Results: What They Mean for Appetite, Lean Mass, and Adherence
The real test for retatrutide is not whether it moves the scale. It is whether it makes the plan easier to follow without flattening training, energy, or lean mass.
9mResearchAdvanced
Peptides Are Moving Into Imaging: What LRRC15 PET Research Says About the Tumor Microenvironment
Peptides are not only treatment candidates anymore. New constrained ligands may help doctors see the tumor microenvironment more clearly, which changes how researchers think about diagnostics, targeting, and drug design.
8mPeptidesIntermediate
Retatrutide, Heat, and the Side-Effect Story: What the New Data Means
Retatrutide's hype is not just about weight loss. The bigger story is the way a triple agonist can feel different, from warmth and energy expenditure to the GI side effects that shape adherence.
9mPeptidesIntermediate
The 2026 Peptide Research Signal Map: 5 Themes That Keep Reappearing
The peptide conversation is crowded. The useful question is which signals keep showing up in the data and which ones are still mostly hype.
9mPeptidesIntermediate
MOTS-C in July 2026: The FDA Review, Human Data, and What to Track
MOTS-C sits at the intersection of mitochondrial signaling, metabolism, and longevity. July 2026 put it back in the spotlight for a reason.
8mPeptidesIntermediate
July 2026 Peptide Research Snapshot: Retatrutide, BPC-157, MOTS-C, GHK-Cu, and Tesamorelin
The peptide space is loud. This snapshot cuts through the noise and focuses on the compounds that still have real biology behind them.
8mPeptidesIntermediate
MOTS-C and Human Mesenchymal Stromal Cells: The Tradeoff Nobody Wanted to Miss
MOTS-C may help metabolic signaling in human cells, but the same signal could come with a repair cost. That matters for anyone reading the longevity hype.
10mPeptidesIntermediate
July 2026 Peptide Research Signals: The 5 Compounds Worth Watching
The most useful peptide research is not the loudest. It is the stuff that changes the question from 'does it work?' to 'who does it help, for what outcome, and with what tradeoffs?'
8mResearchAdvanced
FDA Peptide Compounding Review: What the Seven-Peptide Debate Means for Buyers and Clinics
Regulation does not settle the peptide debate by itself. It forces clearer questions about sourcing, safety, evidence, and who is responsible when claims move faster than data.
9mPeptidesIntermediate
Therapeutic Peptides in Gerontology: What Healthy Aging Research Actually Shows
Healthy aging is not a slogan. It is a measurable question about inflammation, tissue repair, metabolic control, and whether a peptide has human data behind it.
8mResearchAdvanced
MOTS-c and Human Cell Repair: Why Metabolic Signaling Can Come With a Tradeoff
MOTS-c is not just a mitochondrial story. In human cells, the same signal that turns on metabolism may also dampen repair, which makes context matter.
9mResearchAdvanced
Retatrutide and Body Composition: Why the Real Story Is Adherence, Not Just Scale Weight
The best metabolic tools do more than move the scale. They change how easy it is to follow the plan on day 3, day 30, and day 300.
10mResearchAdvanced
Therapeutic Peptides in Orthopaedics: What the New Review Actually Means for Injury Recovery
Orthopaedics is paying closer attention to peptides because the field keeps running into the same problem: recovery is biology, but biology still needs evidence before it becomes a protocol.
9mResearchAdvanced
GLP-1s and Muscle Health: What the Latest Meta-Analysis Means for Body Recomposition
GLP-1 weight loss is not the same as automatic muscle loss. The real story depends on protein, resistance training, and tracking.
9mResearchAdvanced
Tesamorelin and Liver Fat: Why the TESA-LIVER Trial Matters
Tesamorelin has one of the cleanest human-data stories in the peptide space. The new liver fat trial matters because it asks whether that signal extends into fatty liver disease.
8mResearchAdvanced
Retatrutide and Food Noise: Why Appetite Control Changes Adherence
The scale is only part of the story. Retatrutide's biggest advantage may be how it quiets food noise and makes adherence easier to sustain.
8mResearchAdvanced
GLP-1 Muscle Preservation: How to Keep Lean Mass While Losing Fat in 2026
GLP-1s can drive impressive weight loss, but the real win is losing fat without giving up strength. This guide shows how to protect lean mass while appetite is down.
8mResearchAdvanced
Retatrutide and Visceral Fat: Why the Scale Misses the Real Signal
Scale weight is noisy. If you are using retatrutide, waist trend, body composition, protein intake, and strength matter more than a single weigh-in.
9mPeptidesIntermediate
What Real-World GLP-1 Data Actually Tells Us About Safety and Results
Clinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.
8mPeptidesIntermediate
GLP-1s, Delayed Gastric Emptying, and Surgery: What the Perioperative Debate Means
GLP-1s can slow gastric emptying, which is why surgery teams now ask different questions. The key is to understand the risk without turning it into fear or hype.
9mPeptidesIntermediate
MOTS-C and Mitochondrial Repair: Why This Peptide Keeps Showing Up in Recovery Research
MOTS-C sits at the intersection of mitochondrial signaling, glucose control, and recovery biology. Here is what the current research can actually support.
9mPeptidesIntermediate
GHK-Cu, Collagen, and Tissue Remodeling: What the Research Actually Suggests
GHK-Cu is more than a cosmetic peptide. The interesting signal is tissue remodeling, matrix repair, and how that may matter for skin, hair, and recovery.
8mPeptidesIntermediate
MOTS-C and Muscle Mitochondrial Efficiency: What the New Data Means
New MOTS-C data points to something more specific than a generic metabolism story: better muscle mitochondrial efficiency. Here's what that means in practice.
9mPeptidesIntermediate
Retatrutide and Chronic Kidney Disease: What the 2026 Meta-Analysis Adds
Retatrutide is no longer just a weight-loss story. The latest kidney-aware review sharpens the question: which metabolic patients need tighter monitoring, slower escalation, and better data?
8mPeptidesIntermediate
MOTS-c and Cardiac Ischemia-Reperfusion: What the New Rat-Heart Study Shows
MOTS-c is showing up in cardiac stress research. A new rat-heart study points toward mitochondrial bioenergetics, mtDNA integrity, and post-ischemic recovery.
8mPeptidesIntermediate
MOTS-c and Inflammatory Lung Disease: What the New Research Suggests
MOTS-c is moving beyond generic energy claims. New research points toward mitochondrial stress response, lung inflammation, and cardiac reperfusion biology.
8mPeptidesIntermediate
GLP-1s and Biological Aging: What the New Semaglutide Study Shows
GLP-1 research is moving into healthspan and epigenetic aging. The new semaglutide signal is worth tracking, but it is not proof of age reversal.
8mPeptidesIntermediate
MOTS-c and Soft Tissue Survival: What the New Autophagy Study Suggests
MOTS-c is being studied beyond energy and metabolism. New research points toward tissue-stress biology, lysosomal stability, and cell survival under ischemic pressure.
8mPeptidesIntermediate
GLP-1s and Breast Cancer Risk: What the New Signal Means
GLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.
8mPeptidesIntermediate
Amylin and GLP-1: The Next Wave of Metabolic Peptides
The next metabolic peptide wave is not just stronger GLP-1 dosing. Amylin, GIP, glucagon, and combination protocols are changing what serious tracking should include.
7mPeptidesIntermediate
CagriSema and Amylin: Why GLP-1 Stacks Are Changing in 2026
GLP-1 therapy is no longer just GLP-1. CagriSema, cagrilintide, petrelintide, and amycretin show why amylin is becoming a serious metabolic target.
8mResearchAdvanced
Peptide Clinical Evidence in 2026: How to Separate Signal from Hype
Peptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.
8mResearchAdvanced
BPC-157 and Ischemia-Reperfusion Injury: What the 2026 Rat Study Found
New 2026 data puts BPC-157 into a sharper recovery frame: oxidative stress, inflammation, apoptosis, angiogenesis, and the limits of animal evidence.
8mResearchAdvanced
GLP-1s and Macular Degeneration: What the Eye Studies Say
GLP-1 research is moving beyond weight loss. Recent ophthalmology studies suggest possible links with age-related macular degeneration, but the signals are mixed and need careful interpretation.
8mResearchAdvanced
MOTS-c and Atrial Fibrillation: What the 2026 Study Suggests
MOTS-c is moving beyond the generic energy peptide conversation. New 2026 research connects mitochondrial-derived peptides with atrial fibrosis, inflammation, and heart rhythm biology.
8mPeptidesIntermediate
MOTS-c and Arterial Stiffness: What the 2026 Pilot Study Shows
A new MOTS-c pilot study adds a vascular-health signal to the mitochondrial peptide conversation, but it should be read as biomarker research, not a protocol claim.
7mResearchAdvanced
GLP-1s Before Bariatric Surgery: What the 2026 Evidence Says
GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.
8mResearchAdvanced
GHK-Cu Topical Gel Trial: What Wound Healing Data Could Show
GHK-Cu is moving beyond skin-care hype into a controlled wound-healing study. Here is how to read the Phase 2 trial without overclaiming the result.
8mResearchAdvanced
MOTS-c and Mitochondrial Metabolism: What the 2026 Human Trial Is Testing
MOTS-c is one of the most interesting mitochondrial peptides in 2026 because the question is finally shifting from mechanism to human outcomes.
8mResearchAdvanced
Retatrutide TRIUMPH-1 Phase 3 Results: How to Track the 28.3% Weight Loss Data
The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.
7mResearchAdvanced
Peptide Regulation and Sourcing Safety in 2026
The biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.
7mResearchAdvanced
GHK-Cu: Beyond Anti-Aging — The Regenerative Peptide Rewriting Wound Care
A 2025 Biomaterials Research paper shows GHK-Cu hydrogel achieving full infected wound healing — antibacterial, anti-inflammatory, and neovascularization effects. Here's what the mechanism actually means for regenerative protocols.
8mResearchAdvanced
BPC-157 and GLP-1 Side Effects: What the Research Really Shows
GLP-1 receptor agonists cause nausea in up to 44% of users and it is the top reason for discontinuation. Here is what the research shows about BPC-157 as a potential gut protectant, and where the evidence stops.
7mResearchAdvanced
The Multi-Peptide Stack: What 2026 Peer-Reviewed Science Actually Shows
Two 2026 peer-reviewed reviews in Sports Medicine and JAAOS now formally catalog BPC-157, TB-500, GHK-Cu, CJC-1295, and Ipamorelin stacks. Here is what the science actually shows — and where the gaps still are.
7mPeptidesIntermediate
MOTS-c and NAD+: The Mitochondrial Longevity Pair Gaining Serious Scientific Attention
MOTS-c is a peptide encoded in your mitochondrial DNA that declines with age and mimics exercise benefits in animal studies. NAD+ has actual human clinical data. Here's what 2026 research shows about why these two molecules may work together — and what's still missing.
7mPeptidesIntermediate
Dapiglutide: What the GLP-1/GLP-2 Obesity Trial Means
Dapiglutide is not another simple GLP-1 copycat. The early 2026 trial missed statistical significance for weight loss, but the mechanism points toward the next phase of peptide design.
8mResearchAdvanced
Tirzepatide vs. Semaglutide: What the 2026 Data Actually Shows
New head-to-head trials and real-world data from 2025-2026 reveal tirzepatide and semaglutide are not equivalent - they produce meaningfully different outcomes depending on your goals.
7mResearchAdvanced
BPC-157 Hits a Milestone: The First Controlled Human Trial Is Now Recruiting
After 30+ years of animal research and 212 preclinical studies, BPC-157 has entered its first Phase 2 human trial. Here's what it will test, what it won't prove, and what to track.
7mResearchAdvanced
Injectable Peptide Safety Checklist: What Doctors Want Patients to Know in 2026
AMA and FDA updates make one thing clear: peptide interest is moving faster than human evidence, dosing standards, and product-quality controls. Use this checklist before trusting a vial.
9mResearchAdvanced
SLU-PP-332: The ERRα Agonist That Gives You the Benefits of Exercise in a Vial
SLU-PP-332 is a small-molecule ERRα agonist with remarkable endurance, fat oxidation, and mitochondrial benefits. Here's the complete guide to what it does, who it's for, and how to use it.
8mResearchAdvanced
Selank and Semax: The Complete Protocol for Calm Focus and Cognitive Enhancement
Selank and Semax are two of the most powerful intranasal nootropic peptides available. Here's how they work, how they differ, and the best protocols for using them separately or stacked.
9mPeptidesIntermediate
Semax: The Neuroprotective Peptide Changing Cognitive Research
Semax is an ACTH-derived peptide that upregulates BDNF and supports neuroprotection. Here's what the research actually shows — and how to track your cognitive protocol.
8mResearchAdvanced
Tesamorelin and Visceral Fat: What the 2026 Meta-Analysis Shows
Tesamorelin has one of the stronger human-data profiles in the peptide space. A 2026 meta-analysis helps clarify what it improves, what it does not, and how to track the signal honestly.
7mResearchAdvanced
GLP-1 Lean Mass Loss: What 2026 Data Shows
A new 2026 meta-analysis puts real numbers on lean mass change during semaglutide, tirzepatide, and liraglutide weight loss. The practical takeaway is not panic. It is better tracking.
8mResearchAdvanced
BPC-157 Human Hamstring Trial: Why This Study Matters
BPC-157 finally has a registered human sports-injury study. The signal is important, but it is not proof yet. Here is how to read the trial without the hype.
8mResearchAdvanced
Wellness Peptides and the Evidence Gap: What ECRI and ISMP Warned
A new ECRI and ISMP warning says popular wellness peptides are being marketed faster than the evidence can support. Here is how to separate compound science from product risk.
8mResearchAdvanced
Health Canada Peptide Warning: What Buyers Should Know
Health Canada's 2026 public advisory names unauthorized injectable peptides sold online and explains why product quality, legal status, and medical supervision matter.
8mResearchAdvanced
Retatrutide Trials in 2026: Back Pain, Liver, Heart, and Muscle Signals to Watch
Retatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.
8mResearchAdvanced
Peptide Therapy for Sports Injuries: What 2026 Evidence Really Shows
A new sports medicine review puts injury-recovery peptides in context. Some mechanisms are promising, but human evidence, safety data, and regulatory status still matter.
8mResearchAdvanced
GLP-1 Nutrition Strategy: Protein, Muscle, and Labs
New 2026 reviews show a nutrition gap in GLP-1 and incretin therapy research. Here is how to protect protein intake, lean mass, hydration, and labs while appetite is suppressed.
7mResearchAdvanced
Efsubaglutide Alfa SUPER1 Trial: What the New GLP-1 Data Shows
Efsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.
7mSafetyIntermediate
Peptides and Ehlers-Danlos Syndrome: What to Know Before You Experiment
EDS changes the safety conversation around peptides. GHK-Cu, BPC-157, and TB-500 are discussed for tissue support, but EDS plus cardiac history should stay clinician-led.
9mResearchAdvanced
Retatrutide TRIUMPH-4: 28.7% Weight Loss and Osteoarthritis Relief in One Peptide
The TRIUMPH-4 trial delivers groundbreaking dual benefits: 28.7% body weight reduction plus significant osteoarthritis pain relief. Retatrutide's triple mechanism may solve two problems simultaneously.
9mResearchAdvanced
BPC-157 and TB-500 for Torn Meniscus Recovery: Real Case Report
A torn meniscus and Baker cyst — both resolved without surgery. This Reddit case report shows what BPC-157 and TB-500 can do for knee injuries. But the clinical picture is more complicated than a success story.
5mPeptidesBeginner
How to Reconstitute and Dose NAD+: A Practical Guide
Learn the proper technique for reconstituting NAD+ vials, understanding concentration calculations, and building an effective dosing protocol for your research needs.
7mResearchAdvanced
Retatrutide Trial Participant Hit 31% Total Body Weight Loss: What the Number Actually Means
31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.
9mResearchAdvanced
GLP-1 Food Noise: Why It Comes Back After Stopping and What Actually Helps
Food noise — that constant mental chatter about food — often comes back after stopping GLP-1 peptides. Here's the science of why, and what actually helps: maintenance strategies, stacking options, and realistic expectations.
9mResearchAdvanced
Retatrutide Phase 3 Results: 28.7% Weight Loss Sets New Standard
New Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.
11mProtocolsIntermediate
BPC-157 + TB-500 Stacking Guide: Complete Injury Recovery Protocol
BPC-157 and TB-500 are the most researched peptides for connective tissue repair—but combining them requires understanding their different mechanisms. Here's the complete stacking protocol based on actual user experience.
8mResearchAdvanced
FDA Warning Letters Signal a New Era for Peptide Buyers
Seven FDA warning letters in April 2026 show regulators are paying closer attention to online peptide sellers, especially research-use-only marketing that looks like consumer health claims.
9mResearchAdvanced
GLP-1 for Weight Loss Without Diabetes: What the 2026 Systematic Review Found
You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.
9mResearchAdvanced
Peptides for Psoriasis and Autoimmune Skin Conditions: What the Research Shows
Psoriasis affects 125 million people worldwide. While peptides aren't a cure, emerging research suggests certain compounds may help calm inflammation and support skin repair. Here's what the science says.
9mResearchAdvanced
RFK Jr., the FDA, and BPC-157: What the 2026 Regulatory Reversal Means for Peptide Access
After years of FDA crackdowns on research peptides, a significant regulatory reversal in 2026 has changed the landscape for BPC-157, TB-500, and MOTS-C. Here's what actually happened and what it means for you.
8mStart hereBeginner
503a vs 503b vs Unapproved Peptide Status: What's the Difference?
Confused about peptide compounding categories? This guide breaks down 503a compounding pharmacies, 503b outsourcing facilities, and why “research use only” is not a consumer pathway PeptIQ endorses.
8mPeptidesIntermediate
GHK-Cu vs Minoxidil: The Copper Peptide That Outperformed the #1 Hair Loss Treatment
Most people fighting hair loss default to minoxidil. But a 2022 clinical trial showed a 0.5% GHK-Cu serum increased hair count by 22% over 16 weeks — beating 3% minoxidil. And GHK-Cu doesn't just grow hair. It works at the genomic level.
7mPeptidesIntermediate
FDA Removes GHK-Cu from Category 2: What Peptide Users Need to Know
On April 15, 2026, the FDA announced it will remove injectable GHK-Cu from Category 2 — the list that blocked compounding pharmacies from producing it. This is a major regulatory shift for one of the most studied copper peptides in longevity research.
8mPeptidesIntermediate
MOTS-C Daily vs Weekly Dosing: Which Protocol Works Best?
The MOTS-C dosing debate is real: 0.5-1mg daily vs 5mg 2-3x weekly. Both protocols have their advocates. Here's what the research says, why context matters, and how to choose the right approach for your situation.
7mProtocolsIntermediate
Cerebrolysin SubQ vs IV: Which Route Works for Cognitive Enhancement?
Grok says subQ Cerebrolysin doesn't work due to volumes. The real answer is more nuanced — and subQ is viable at research doses if you use the right solvent.
9mPolicyAdvanced
FDA Reclassifies 12 Peptides: What April 2026's Policy Shift Means for Biohackers
The FDA's April 15, 2026 reclassification of 12 research peptides marks the most significant regulatory shift in the space since the 2023 compounding crackdown. Here's a breakdown of the affected compounds, the new compliance landscape, and how to think about your protocol going forward.
10mPeptidesIntermediate
MOTS-C Long-Term Use: Does Your Body Stop Responding?
MOTS-C activates AMPK and drives mitochondrial adaptation — but does daily use over months cause your body to stop responding? Here's what the research and user experience actually says about long-term MOTS-C protocols.
8mProtocolsIntermediate
Long-Term MOTS-C Use: Cycling, Receptor Sensitivity, and What to Expect
MOTS-C is mitochondria-encoded and activates AMPK through a pathway that's less prone to classic receptor downregulation. Here's how to structure long-term use for sustained results.
9mPeptidesIntermediate
Epitalon: The Telomere Peptide That Actually Has Research Behind It
Epitalon is a synthetic tetrapeptide developed from pineal gland extract that activates telomerase and has decades of Khavinson research behind it. Here's what it does, how to dose it, and how to stack it.
9mPeptidesIntermediate
GHK-Cu and Cognitive Aging: New Research on the Copper Peptide's Brain Benefits
GHK-Cu has long been known for its skin and healing benefits. A fresh April 2026 preprint adds a surprising new dimension — cognitive aging reversal in mouse models via BDNF upregulation and neuroinflammation suppression.
9mResearchAdvanced
Why Your Weight Isn't Moving on Retatrutide (And What to Do About It)
Hitting a plateau on Retatrutide is common and usually temporary. Here's the science behind GLP-1 stalls and the practical steps to break through them.
9mResearchAdvanced
BPC-157 Human Trial: 87.5% of Knee Pain Patients Report Significant Relief at 6–12 Months
87.5% of patients with chronic knee pain reported significant relief after BPC-157 treatment at the 6–12 month follow-up. Here's a breakdown of the human trial data, the dosing protocol used, and why this peptide is getting serious clinical attention.
8mPeptidesIntermediate
Should You Cycle NAD+? The Complete Guide to NAD+ Protocols
Most people who take NAD+ daily wonder whether they should cycle it. The answer isn't black and white — it depends on your dose, delivery method, and goals. Here's what the research and community experience actually suggest.
8mPeptidesIntermediate
Epithalon (Epitalon): The Longevity Peptide That May Extend Your Telomeres
Epithalon is one of the most researched longevity peptides in existence, with decades of clinical data behind it. This guide covers the science of telomere elongation, dosing options, cycling protocols, and how it fits into a modern anti-aging stack.
8mPeptidesIntermediate
BRP Peptide: Stanford's AI-Discovered 'Natural Ozempic' Explained
A Stanford AI tool screened 2,600 uncharacterized peptides and identified BRP — a 12-amino acid molecule that cuts food intake by up to 50%, promotes fat burning, and avoids the nausea, constipation, and muscle loss common with GLP-1 drugs. Here's what the research actually shows.
10mProtocolsIntermediate
Peptide Protocols for Women Over 40: The Complete Recomp and Anti-Aging Guide
Most peptide guides are written with a 35-year-old man in mind. If you're a woman in your 40s or 50s lifting hard and trying to recomp, the stack looks different. Here's what the research actually supports.
9mPeptidesIntermediate
Tesamorelin: The Science-Backed Growth Hormone Peptide for Fat Loss and Longevity
Tesamorelin is an FDA-approved GHRH analog with clinical trials proving 15–20% visceral fat reduction. Here's the full science, dosing guide, and what the latest research reveals about its longevity applications.
9mResearchAdvanced
Cerebrolysin: Dosing, Reconstitution, and What to Expect
Cerebrolysin is a brain-derived peptide mixture used for neuroprotection and cognitive enhancement. Here's what the research says, how to reconstitute it, and what real protocols look like.
9mPeptidesIntermediate
MOTS-c Enters Phase 2a Human Trial for Prediabetes: What the Research Shows
MOTS-c — a peptide synthesized inside your own mitochondria — is now in Phase 2a human trials for prediabetes. Early data suggests it improves insulin sensitivity and metabolic flexibility without the side effects of pharmaceutical interventions.
8mResearchAdvanced
Dihexa: The Most Potent Nootropic Peptide You've Probably Never Heard Of
A complete breakdown of Dihexa — mechanism of action, dosing, what users actually report, and how it compares to Semax and Selank for cognitive enhancement.
9mPeptidesIntermediate
MOTS-c: The Mitochondrial Peptide Rewriting Longevity Science
Discovered inside mitochondrial DNA itself, MOTS-c is one of the most fascinating longevity peptides in modern science. It governs how your cells produce energy, fight fat accumulation, and age.
10mPeptidesIntermediate
36 Studies Confirm BPC-157 Heals Musculoskeletal Tissue: What the New Systematic Review Found
The largest systematic review of BPC-157 to date analyzed 36 studies and confirmed consistent healing outcomes across tendons, ligaments, bone, and muscle tissue. Here's what the data shows.
7mPeptidesIntermediate
GHK-Cu Dosing Guide: How to Use Copper Peptide for Skin, Healing, and Longevity
GHK-Cu is one of the most researched anti-aging peptides available. Here's a practical dosing guide covering protocols, cycle length, stacking, and what to realistically expect.
9mResearchAdvanced
Retatrutide TRIUMPH-4 Phase 3 Trial: 28.7% Body Weight Reduction Confirmed
Phase 3 data is in: retatrutide produced an average 28.7% body weight reduction — roughly 71 lbs — in the TRIUMPH-4 trial. Here's what the numbers mean and how the triple agonist mechanism drives these results.
11mPeptidesIntermediate
BPC-157: The Peptide That Regenerates Tissue—Science, Clinical Evidence, and Real Results
BPC-157 activates multiple tissue repair pathways simultaneously. Users report faster recovery from injury, improved gut healing, enhanced joint mobility—backed by published clinical data.
10mResearchAdvanced
Retatrutide TRANSCEND Trial: What the Phase 3 Data Actually Shows
TRANSCEND confirmed retatrutide as the most effective GLP-1 class compound tested in late-stage trials. 16.8% mean body weight reduction and a 2.0-point A1C drop in 40 weeks — here's what the full data shows.
9mPeptidesIntermediate
BPC-157 and Wound Healing: The Science Behind the 'Body Protection Compound'
BPC-157 accelerates tissue repair by stimulating angiogenesis and collagen synthesis. Here's what the research shows and what users need to know.
14mPeptidesAdvanced
Peptides for Longevity: The Emerging Science Behind Age-Reversal Compounds
The peptide space is shifting from weight loss toward longevity. Explore the science behind peptides designed to slow aging, repair cellular damage, and extend healthspan.
10mPeptidesIntermediate
Latest Peptide Research Breakthroughs: What's Coming in 2026
The peptide space is evolving rapidly. Here's what researchers are discovering, which new compounds show promise, and what breakthroughs could hit the market soon.
10mPeptidesIntermediate
Why Retatrutide Preserves Muscle Better Than Tirzepatide
Rapid fat loss typically means muscle loss. But retatrutide's triple action—including glucagon receptor activation—preserves more lean mass than tirzepatide or GLP-1-only compounds. Here's the science.
12mPeptidesIntermediate
Retatrutide vs Tirzepatide: What the Latest Clinical Data Shows
Retatrutide and tirzepatide dominate the peptide conversation, but they're not interchangeable. Here's what the latest clinical research reveals about their differences, efficacy, and mechanisms.
10mPeptidesIntermediate
BPC-157: The Peptide That Heals Joints, Ligaments, and Muscle Faster
BPC-157 is showing remarkable promise in clinical research for rapid tissue regeneration. Learn how this pentapeptide works, what the data shows, and whether it's right for your recovery protocol.
8mPeptidesIntermediate
Retatrutide Phase 3 Results: What the Clinical Data Tells Us
New Phase 3 data shows retatrutide delivering superior metabolic benefits. Here's what researchers found and why it matters.
12mPeptidesIntermediate
BPC-157: The Tendon Recovery Peptide Backed by Clinical Research
BPC-157 shows promise in clinical research for accelerating tendon repair and recovery. Learn how this peptide works and what the science says about its efficacy.
9mResearchAdvanced
Retatrutide 2-Year Weight Loss Durability: What the Latest Data Shows
Retatrutide is showing remarkable 2-year durability for weight loss. Here's what the science says and what it means for your protocol.
12mPeptidesIntermediate
BPC-157: Complete Guide to Benefits, Dosage, and Research
Explore the healing peptide BPC-157, nicknamed the 'Wolverine peptide' for its remarkable regenerative properties.
12mPeptidesIntermediate
Growth Hormone Peptides for Anti-Aging: The Science Explained
Discover the scientific foundation behind using GH peptides for anti-aging and longevity optimization.
10mResearchAdvanced
How to Read Peptide Research: Understanding Studies and Claims
Develop the skills to critically evaluate peptide research and distinguish solid science from marketing hype.
Also available at /blog for legacy links.